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We present two new modalities for generating chemical maps. Both are mid-IR based and
aimed at the biomedical community, but they diﬀer substantially in their technological
readiness. The ﬁrst, so-called “Digistain”, is a technologically mature “locked down” way of
acquiring diﬀraction-limited chemical images of human cancer biopsy tissue. Although it is
less ﬂexible than conventional methods of acquiring IR images, this is an intentional, and
key, design feature. It allows it to be used, on a routine basis, by clinical personnel
themselves. It is in the process of a full clinical evaluation and the philosophy behind the
approach is discussed. The second modality is a very new, probe-based “s-SNOM”, which
we are developing in conjunction with a new family of tunable “Quantum Cascade Laser”
(QCL) diode lasers. Although in its infancy, this instrument can already deliver ultra-detailed
chemical images whose spatial resolutions beat the normal diﬀraction limit by a factor of
1000. This is easily enough to generate chemical maps of the insides of single cells for
the ﬁrst time, and a range of new possible scientiﬁc applications are explored.1. Introduction
The principles of vibrational spectroscopy, (VS), have been established over
several decades, and, for much of this time, reliable oﬀ-the-shelf systems have
been available that are capable of delivering high quality spectroscopic image (SI)
datasets for use by the biomedical community. These datasets have potential
utility over a wide range of biomedical disciplines that include histopathology,
cytology, surgical targeting and drug discovery.1
Very recently, technical advances in array detectors and in tuneable “Quantum
Cascade laser” (QCL) narrow line sources have opened up new lines ofaPhysics Dept., Imperial College, London, SW7 2AZ, UK. E-mail: Chris.phillips@imperial.ac.uk; Tel: +44 (0)207
594 7575
bDepartment of Cancer and Surgery, Faculty of Medicine, ICTEM, Room 145, Du Cane Road, London W12 0NN,
UK
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View Article Onlineexperimentation, andmost would agree that the mid-IR part (3 mm < l <10 mm)
of the spectrum is experiencing, in technology terms, a renaissance. On the other
hand, the reality is that take-up of these technologies by the biomedical scientists
themselves, particularly clinicians, is still modest.
This paper starts by examining possible reasons for this, (with the aim of
stimulating discussion), to set a context within which IR SI implementations may
be evaluated for their genuine biomedical potential. It concludes by using this
context to examine two new VS-based imaging technologies that we have devel-
oped. They are at roughly opposite ends of the labyrinthine “translational
pathway” that, ideally, can take a technology from the physical science research
lab into the clinic.
The rst example, the so-called “Digistain” imager, is a very simple, stripped-
down, SI system that is currently at the clinical validation stage. It arose when,
rather than asking the usual scientists/technologists question, i.e. “How can I
apply my new research technology in a new and hopefully useful way?” we tried
inverting the argument and, instead, asked the question “Can we use our research
expertise to develop a system that really could end up being used by clinicians?”
Over the course of a 10 year multidisciplinary development programme, we found
that this second question demands a far more considered and complex answer
than the rst. Hopefully we will show how well such a simple incarnation of SI
technology can perform in a genuine sharp-edged clinical trial environment.
The second example is a new, probe-based, SI system that is very expensive and,
at the moment, very diﬃcult to use. It is formed by marrying an existing high-end
commercial s-SNOM (scattering-type Scanning Near-eld Optical Microscope)
machine to an array of newly available QCL diode lasers. It can deliver SI datasets
down to a l/1000 spatial resolution of 10 nm, i.e. suﬃcient to generate chemical
maps inside a single cell for the rst time. It came into being in a more traditional
way, i.e. by asking the rst of the two questions discussed above. Although we believe
it has the potential to deliver game-changing imaging performance across the
biosciences, it is at a very early stage, and at the moment we can only give a selection
of demonstration images that hint at its potential in the biomedical arena.1.1 Issues aﬀecting the translation of VS technologies into the biomedical
arena
There are several issues that came into prominence while we were trying to answer
the “Can we use our research expertise, to develop a system that really could end
up being used by clinicians?” question, and we choose to list them here. Some
may seem obvious, but we generally underestimated their importance, and oen
we chose to ignore them until it became clear that to do so was no longer tenable.
In retrospect, we believe that, if one is genuinely interested in seeing VS tech-
nology applied in a biomedical setting, much eﬀort and resource can be saved if
one is prepared instead to face these issues as early and as honestly as possible.
1.1.1 Operator dependence and reproducibility. The central question here can
be framed as “Can you genuinely envisage an incarnation of your technology that
could be used by a clinician, and in a way that would give the same answer every
time?” A more dramatic way to put it might be “Would you stake your life on the
reproducibility of your technology?” This outwardly simple technical question is
oen the show-stopper because regulatory procedures will demand that you can540 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
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View Article Onlineprove that you can answer it in the aﬃrmative. It is a purely technical question, and
long before regulatory approval becomes an issue, you will have to convince inves-
tors that, at some stage, you will be able to deliver a positive answer to it. If they
cannot be convinced, all commercialization prospects will wither, and no matter
how powerful the technology is, it will simply never leave the developers lab.
Because this issue is so central, simplied and well-understood data acquisi-
tion and processing protocols become paramount. This is true even if, to tech-
nologists, they appear to be technically inferior to more sophisticated approaches.
Only the former can be heuristically tested, and then tightly specied, and written
into a so-called “Standard Operating Procedure”.
This “SOP” document is critical and it has to be able to “lock-down” the
procedures in a way that limits variability to acceptable levels when the
measurements are performed with diﬀerent machines, in diﬀerent labs, and by
diﬀerent people. A successful trial should not be thought of as validating a tech-
nology, but rather it validates a technology paired with a SOP. For VS-based
technologies, one of the biggest problems comes with so-called “unsupervised” SI
data processing methods, because variations, e.g. in image uniformity or signal-
to-noise (SNR) ratio, can have completely unpredictable eﬀects on the data
components that the soware settles on in the course of its data analysis.18
1.1.2 “Occam's razor” and the quest for technology validation. Vibrational
spectroscopies and SI technologies deliver huge and rich datasets, and this is
oen cited as one of their strengths by the scientic community. In most practical
applications however, the overwhelming majority of this data will have to be
discarded and the central question then becomes how this should be achieved.
In clinical settings the degree of data reduction becomes especially extreme.
Medical practitioners are already factoring in huge quantities of “so” informa-
tion when they, say, reach a diagnosis, or decide on a patient's treatment plan. As
a consequence, any new technologies that hope to augment the clinical process
will likely have to boil an extremely complex informational dataset down to
a simple yes/no decision, or, at most, a number on a scale of 1 to 10. If this is not
done, the data is unlikely to be of realistic use to a clinician.
The problem with SI technologies is the huge, (eﬀectively innite) parameter
space. There are so many potential ways to reduce the SI data that a form of data
paralysis can take hold. A chicken-and-egg problem can set in when it becomes
clear that it will be impossible to explore all the possible ways of reducing the
dataset to nd the best one.
For clinical applications this problem is compounded by the fact that the
details of the SOP have to be completely “locked down”, (and given adequate IP
protection), before any clinical trials can be started. Even slight changes to the
SOP will be deemed by the clinical profession to invalidate previously acquired
trial data that were taken with the previous SOP. The result is that one has to “nail
ones colours to the mast” as early as possible.
All these factors, coupled with the fact that resources are always limited in
realistic development programmes, mean that the way forward is likely to involve
a substantial degree of educated guesswork and/or some very pragmatic decision
making. Ideally this will be guided by a knowledge of the physical/chemical/
physiological mechanism that is underpinning the discriminating or diagnostic
power of the SI dataset. Oen though this understanding is either partial or
completely absent. In this case, decisions can be just as usefully driven byThis journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 541
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View Article Onlinetechnological considerations, such as the limitations of available IR sources and
detectors.
1.1.3 Giving biomedical professionals VS-based information in a form they
can use. The point has already been made that clinicians are already factoring
large amounts of information into their clinical decisions. Most of this is quali-
tative, and is generated by the clinicians themselves, via their own senses. Very
little of it is couched in the language of numbers favoured by scientists and
engineers, and most clinicians reach their decisions almost entirely from data
that reaches them in the form of images. This is unlikely to change in the fore-
seeable future.
Moreover, in most cases (e.g., conventional X-ray images, biopsy microscopy,
CAT scans, ultrasonic images, MRI etc.), the image data is evaluated almost
entirely by eye. The clinician does not, (and does not need to) understand e.g. the
contrast mechanisms, or spectroscopic details that generated the image, in order
to be able to exploit its clinical value. Even if the images are available in a reliably-
calibrated digitized format (and usually they are not), it is unusual for any
numerical data to be extracted from them for diagnostic purposes; perhaps the
measurement of a physical dimension, or some single-digit index gure.
Taken together, these facts argue strongly for the VS community to concentrate
on ways of presenting their spectroscopic information to clinicians in a simple,
clear, visual way, probably sweeping all the technical details into the background.
1.1.4 Technology innovation vs. “unmet need”. At some point, perhaps
halfway along the metaphorical “translational path”, the language of the debate
changes abruptly from issues that can be characterized by questions like “How
good is this technology, say compared with the competition?What new things can
it do?” that initially drives we technology developers, to a “What existing problem
can it actually solve?” issue. Thenceforward, funders, investors and users all focus
on the so-called “unmet need”, i.e. the problem, and one that is agreed by the
users as being an existing and important one, which the new technology can
reasonably hope to address.
The key point is that the “unmet need” exists entirely independently of the
technology. It was probably there even before the technology was developed. It is
dened by consensus of the potential users of a technology, and not by our
community of technology developers.
If such an “unmet need” can be identied early on it can have a dramatic eﬀect
on the trajectory of a technology and save much wasted eﬀort. This may seem so
obvious as not to need saying, but the reality is that many, if not most, VS-based
technology development programmes, target an “application” that was chosen,
sometimes even invented, by the technology developer themselves. Usually this is
done without suﬃcient (or, sometimes, any) discussion with potential end users.2. The “Digistain” IR imager, for cancer detection
and diagnosis
2.1 Background and the “unmet need”
At the moment, 99% of cancers are detected and characterised by excising a small
“biopsy” tissue sample from the patient, drying it, slicing it thinly (mm), and
staining it with two vegetable dyes that the histopathology community settled542 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
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View Article Onlineupon over 100 years ago. Haematoxylin stains the acidic parts of the specimen (i.e.
the cell nuclei) blue, and eosin stains the cytoplasmic proteins pink. A trained
histopathologist then “grades” this “H + E” specimen by eye, in a standard optical
microscope. These “grades” oen inform life-critical treatment decisions.
Although the grading SOP protocols vary between diﬀerent cancers, always the
judgements are subjective, and oen there is poor concordance between histo-
pathology practitioners. Considered worldwide, this constitutes a very signicant
“unmet need”.
2.2 The physical principles behind “Digistain”
Our Digistain imager uses the physics of mid-IR absorption in the same excised
and dried tissue slice as a quantitative way of mapping out the ratio of phosphate
moieties, found predominantly in cell-DNA,2 to the proteins in the cell cytoplasm.
The chemical concentrations are measured by taking a set of calibrated images in
four mid-IR bands2 (Fig. 1). The resulting chemical map is converted into
a computer generated false colour image3 and presented to the histopathologist
in a way that allows it to be used to augment and inform the process of tissue
grading.
The idea seems simple, but in execution it presents signicant technical
challenges. Reproducibility requires that the eﬀects of non-uniformity and non-
linearity in the detector array, together with variations arising from non-uniform
sample illumination, and uctuating thermal background signals, all have to be
identied and engineered out.4 Also the 4 images, which are taken at widely
separated wavelengths, have to be accurately calibrated and registered for the
ratioing process to work. Finally the optical throughput and image acquisition
has to be rened to the point where adequate SNR images can be obtained with
practical acquisition times of only a few minutes.
2.3 Factors aﬀecting likelihood of successful clinical application
The choice of these two particular chemical moieties for Digistain was deter-
mined by a mix of the factors outlined in the previous section. In the rst place,
they give prominent features in the IR spectra that are within reach of a combi-
nation of comparatively basic (i.e. uncooled) mid-IR emitters and detectors. This
added to their attractiveness as the features of the dataset most worthy of
preserving in the face of the “Occam's razor” principle (Section 1.2.2).
Secondly, these features provided an image that could be thought of as being
an approximate analogue of the existing H + E one. The concentration of the
phosphate moiety correlates with the acidic components in the tissue that turn
out blue in the H + E images, and the amide moiety correlates with eosinophilic
components of the tissue that stain pink. This way we aimed to reduce the SI
image data to a form that was “pre-digested” into a format that was best suited for
the histopathologists to assimilate and use, in line with the considerations of
Section 1.2.3.
Thirdly, we only settled on this subset of the possible SI data aer having
already undergone a science-driven research programme consisting of several
years of technologically complex laser based spectroscopy.5,6 Although this early
study itself did little to establish a route to a viable clinical application, it had
involved numerous consultations with histopathology professionals. These earlyThis journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 543
Fig. 1 Lower trace, a typical absorption spectrum of dried, unstained, human biopsy
tissue, in this case, a 2.5 mm  2.5 mm section of an oesophageal biopsy section, initially
harvested using a standard “FFPE” (formalin ﬁxed paraﬃn embedded), protocol, then
subsequently deparaﬃnised. It is recorded at 4 cm1 spectral resolution with an FTIR
microscope. Upper trace, transmission spectra of the 4 bespoke mid-IR bandpass ﬁlters
used in the “Digistain” imager. They work in pairs to acquire calibrated signal and baseline
images at wavelengths corresponding to absorption by the amide I and phosphodiester
chemical moieties.
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View Article Onlineconsultations allowed us to identify and roughly target an important histopa-
thology “unmet need” (Section 1.2.4), and steered the design principles behind
the prototype imager of Fig. 2.
Fourthly, although there are of course many types of cancers it is well known
that, in the majority of them, the cell reproduction cycle becomes signicantly
disrupted as healthy tissue becomes diseased. This is reected in the fact that
histopathologists frequently employ measures of both “pleomorphism” (changes
in the relative size and shape of the cell nuclei) and “mitotic activity” (the rate of
cell division) as key factors in their tissue grading SOPs. The “Digistain Index” (DI)
that our imager measures is proportional to the ratio of concentrations of the
phosphate to amide moieties, so we had grounds for hoping that a robust way
could be found to correlate this data with tumour grade.7–9 In other words we were
using an educated guess (Section 1.2.3) to prejudge the data reduction process
that would generate the most useful images, before committing to large-scale
clinical trials.
Fihly, with Digistain we were focussed on an optical measurement, i.e. mid-
IR absorption in a smooth-sided tissue slice, which we could reasonably hope to
be able to make with good robustness and reproducibility (Section 1.2.1). By
taking an appropriately scaled and background corrected ratio3 of the absorption544 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
Fig. 2 Schematic of fully automated “Digistain” IR imager for histopathology. At the base
(LHS) of the unit is a broadband thermal IR source with an electronically controllable
shutter. The IR beam then passes through a set of bespoke, computer-selectable,
narrowband IR ﬁlters, and then through a germanium condenser lens carefully designed to
maximize the optical throughput. The biopsy sample is mounted on a 25 mm diameter
BaF2 disc and is imaged, through a custom designed low aberration imaging optic, onto
a bolometric focal plane array with a magniﬁcation of 3.1 and at a diﬀraction-limited
spatial resolution. The instrument has a 30  30 cm bench footprint, requires only a single
13 A socket, and can be operated, with a single mouse click, by untrained personnel.
Paper Faraday Discussions
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
1/
07
/2
01
6 
13
:2
6:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineof the moieties (Fig. 3) we could design a new SOP (3) that would be least sensitive
to operator-dependent factors. The latter are mostly due to variations in the
thickness of the tissue slice, but there is also the issue of xing protocols, which
can vary from site to site.
Sixthly, the Digistain approach presents the mid-IR spectroscopic information
visually, and in a way that can readily be compared with existing H + E slidesFig. 3 Example of the discriminating power of a Digistain image, in this case of an
oesophageal biopsy. Left: Conventional “H + E” stained biopsy section. The regions
delineated with red dotted lines are epithelial tissue, and the upper one is healthy (as
judged by a trained histopathologist), whereas the lower right one is dysplastic. Right:
Corresponding “Digistain” image, taken from an unstained slice of tissue directly adjacent,
on the FFPE tissue block, to the one used for the H + E stain. It is a false-colour image
constructed from themeasured “phosphide-to-amide” ratio, P/A, extracted from themid-
IR images, as described in Fig. 1 and 2. The healthy tissue shows up blue, and the dysplastic
tissue green. Averaging this “P/A ratio” (which we call the “Digistain Index”, DI), over the
pixels in the two black rectangular areas gives numerical values for the two tissue types
that diﬀer at the >33s level.
This journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 545
Fig. 4 Examples of Digistain reproducibility test. (a) and (b) are images of the same slice of
breast biopsy tissue, but with the sample rotated and translated between scans. The
circled areas are the same portion of tissue in each case, and return “Digistain Index” values
of 1.0667 0.009 and 1.061 0.009 (3s limits), implying a technical reproducibility better
than one part in 100. (c) contains three diﬀerent core biopsies taken simultaneously from
the same histological “grade 2” breast tumour. The boxed green areas were identiﬁed as
tumorous by a trained histopathologist on the basis of the corresponding H + E slides. The
“Digistain Index” here is reproducible to DI ¼ 0.576  0.089 across diﬀerent parts of the
tumour.
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View Article Online(Section 1.2.3). There is an important point here; because the H + E slides are the
clinician's so-called “gold standard” they will continue to be used in any event. No
clinician would risk running against the grain of the profession by attempting to
diagnose a condition as serious as cancer using only a revolutionary and untested
technology. Oen we are asked if Digistain can be adapted for in vivo use and the
answer, in the short term at least, is no, at least not without a major engineering
programme on broad spectrummid-IR compliant imaging endoscopes. However,
in some ways this can be seen as an advantage rather than a shortcoming. If we
had, say, produced a machine that required an extra in vivo endoscopy procedure
on top of the established standard biopsy one, it would probably have been much
harder to test it (it would have needed separate live patient trials) in order to get it
adopted.
A critical factor in Digistain's favour is that aer the H + E biopsies have
been examined, the excised tissue samples are chemically preserved in wax
(which can easily be dissolved away many years later), and archived, along with
the original H + E slide, and a full medical history. There are millions of
documented specimens of all types of cancer that one can go back to and study546 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
Fig. 5 Schematic of the mode of operation of a “scattering-type Scanning Near-ﬁeld
Optical Microscope” (s-SNOM). An AFM tip hovers close to the sample surface and
vibrates, vertically, at a frequency u. IR laser light is focused onto the tip region, and
concentrated, into a spatial area roughly corresponding to the tip diameter (inset), by the
“lightning rod” eﬀect. By detecting the portion of the backscattered light ﬂuctuating at 3u
(i.e. a harmonic of the tip vibration), the light backscattered from this small region can be
isolated. An interferometer (with a reference mirror oscillating at U  u) is used to
measure both the amplitude and phase of the backscattered light, from which the optical
properties of the very small sample area that is interacting with the AFM tip can be inferred.
An image is assembled by rastering the AFM tip across the sample in the usual way.
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View Article Onlinewith Digistain. This means it can be tested and validated with logistical and
ethical hurdles that are far lower than if one had to secure access to cohorts of
new live patients to trial it with. Of course the issues of reliability and repro-
ducibility are just as key here; they require longitudinal trials to establish the
degree of chemical stability, specically, as judged by our new imaging
method, aﬀorded by the FFPE method (Fig. 4).
At present we are nearing the end of a clinical trial, involving upwards of 200
breast cancer patients. They were assessed according to the RECIST criteria (a set
regulated assessment criteria that all breast cancer diagnostic methods must
follow), and the biopsies were xed using the RCP (Royal College of Pathologists)
xing protocol. To carry weight with themedical profession, these trials have to be
performed, by a large team, under strict conditions of anonymity, double-blind-
ness and with suitably experienced and accredited statistical analysis staﬀ.
Unfortunately, for this reason, we are not allowed to discuss the results at all until
they have been formally released, but we hope to be able to discuss this in more
detail at the meeting.This journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 547
Fig. 6 Upper; AFM scan of the physical structure of a single red blood cell in a squamous
epithelial oesophageal biopsy. Lower image, s-SNOM 3rd harmonic image, taken at l ¼
9.81 mm, 20 min scan time and 67 nm pixel resolution. The resolution here is 140 times
better than the diﬀraction limit at this wavelength and has allowed us to image chemical
contrast within the cell for the ﬁrst time.
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View Article Online3. A tuneable s-SNOM for intracellular chemical
mapping
3.1 Introductory comments
Typical cells are 10s of mm across, and although mm-level diﬀraction-limited
resolution mid-IR imaging is possible (5) SNR limitations mean that it is only
practical with sophisticated bench-scale laser sources. These are very challenging
to implement, and they still fail to deliver enough resolution to “look inside”
a single cell. In principle, Raman methods can deliver sub-micron resolution, but
the ineﬃciency of the Raman signal generation process means that getting useful
signals from beams that are focussed so tightly involves power densities that are
likely to compromise biological material.
The advent of a cell-level chemical analysis capability would have a wide
ranging impact across the biosciences. At present, chemical analysis of changes to
cell chemistry involve generating a sample of a large number of cells, (say by ow
cytometry or cell breeding), breaking them up, and then analysing the mix with
any one of a number of chemist's tools, including wet-chemistry assay, IR548 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
Fig. 7 (b) AFM topography and (c) l ¼ 10.21 mm s-SNOM scattered amplitude image of
a “natural photonic crystal”, i.e. the shell of an iridescent beetle (a) that has in-built periodic
structure that gives it a chiral light scattering characteristic which means its shell markings
only show up under circularly polarised light. The s-SNOM image has given the chemical
contrast of the components that make up the multilayers in the insect shell. In order to
generate the shell's interference features in the visible part of the spectrum, the
concentrations of these components vary on a sub-micron length scale, and only the s-
SNOM can deliver chemical images at this resolution.
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View Article Onlinespectroscopy, mass spectroscopy or labelling methods. Of course, all these
“looking at the bits” approaches destroy the cell morphology information, and
they necessarily average over any cell-to-cell variation in either chemistry or
morphology.
Real cell-level imaging would have a major impact across the biosciences. The
cell-to-cell variations within a population could give crucial insights into e.g. how
cancer starts, (oen with a single rogue cell), and, generally speaking cell-level
pathology could be radically transformed. In pharmacology, the question of “HowThis journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 549
Fig. 8 (a) AFM topology, and l ¼ 10.3 mm s-SNOM amplitude (b) and phase (c) images of
an FET transistor fabricated from a monolayer graphene (1LG) with occasional bilayer
inclusions (2LG) sheet, etched away in places to reveal the SiC substrate.
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View Article Onlinedoes this drug act?” oen boils down to “Where, and for how long, does this drug
bind?” and being able to answer the latter, at a cell level, could have major
implications for the drug discovery industry.
In this context, ultra-high-resolution imaging oﬀers a unique “concentration
advantage” feature. Fortunately, many pharmacologically active compounds have
distinctive vibrational spectra, but most are active at mean concentrations in the 1
part in 109 region. Obviously this presents a major sensitivity challenge for VS-
based technologies. If the drug binds at a particular site though, the local
concentration can be dramatically elevated, and if the SI resolution is increased to
the point where only a comparatively small number of molecules can be resolved,
this eﬀect can, in principle, li the signal out of the noise.
So-called s-SNOMs promise to deliver this information.10 They work by
focussing mid-IR radiation onto the point where the probe tip of an atomic force
microscope (AFM) touches a sample, and then analysing the degree to which the
radiation is backscattered. The sharpness of the AFM tip concentrates the optical550 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
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View Article Onlineelds, via a “lightning rod” eﬀect, into an area roughly commensurate with the
AFM tip diameter. They oﬀer spatial resolutions down to10 nm even with l 10
mm light, and they work with radiation densities and photon energies that are
both low enough to be completely compatible with biological material.
However, the backscattered signal is small, and it requires a sophisticated
interferometric signal recovery scheme11 (Fig. 5) to pick it up. In turn this
necessitates a coherent IR source. Usually this is a CO2 laser that can only be
tuned over a spectral range that is too narrow for useful IR spectroscopy. Until
recently the only broad-band alternative source was a complex lab-scale laser
system that used non-linear frequency mixing technology,12 or an IR synchro-
tron,13 but now the situation is rapidly evolving with the advent of commercially
available “Quantum Cascade Lasers” (QCLs).
3.1.1 Brief synopsis of “Quantum Cascade Laser” technology. QCLs are a new
type of laser diode14 that use sophisticated semiconductor nano-structuring to
produce a device that can be designed to lase across a wide wavelength range,
from the mid-IR to the THz part of the spectrum. The technology is rapidly
evolving, but at the moment, practical (i.e. operating at close to 300 K) commer-
cially available devices roughly span the 5 mm  l  11 mm range.
However, each device typically tunes through 2 or 3 mm, so covering the normal
mid-IR VS range is expensive because it needs 4 or 5 devices to be engineered into
a single system. CW QCL operation is only available in parts of the spectrum, but
they generate CW-equivalent powers in the mW range, with very narrow line-
widths and close to diﬀraction-limited beam quality. The commercial QCL
systems now oﬀer turn-key operation, coupled to a convenient computer-
controlled tuning system that makes them very easy to use.
Against this however, many of the QCL designs use external cavities for tuning
the lasers, and these are extremely sensitive to small amounts of light being
scattered back from the s-SNOM interferometer. This makes it diﬃcult to get
them to work stably enough to use with the s-SNOM. Also, the fact that some
wavelengths are only available as pulse trains introduces technical complications
to the signal chain15 (as well as for imaging applications more generally) and in
practice, when the QCL system switches between diﬀerent laser devices as it is
tuned, the s-SNOM optics usually have to be manually re-aligned.
3.1.2 Quantum Cascade Lasers applied to s-SNOM. Our s-SNOM system
(NeaSNOM, Neaspec) uses probes with 10 nm tip radius, oscillating at
frequencies in the 50–300 kHz region. A range of QCLs are used, (Lasertune, Block
Engineering, and MirCat, Daylight Solutions), both in CW and pulsed modes.
When the lasers can only operate pulsed, steps have to be taken to synchronise
the laser pulse rate to the sampling rate of the circuitry that digitises the detector
signal, in order to avoid introducing large amounts of digitisation noise.15
Depending on the application, the backscattered light is polarised before
being detected. In “plasmonic” experiments s-polarised incident light is used,
because it can excite plasmonic modes in metal nanostructures without being
sensitive to chemically based contrast mechanisms that arise between the
diﬀerent material components (usually a metal and a dielectric) that are used to
make the nanostructure. If the detection channel is then p-polarised, (the so-
called “cross polarisation scheme”) it selects only the p-polarised eld compo-
nents that arise from the excitation of plasmons in the nano-photonic device, and
is largely immune to chemical contrast eﬀects.This journal is © The Royal Society of Chemistry 2016 Faraday Discuss., 2016, 187, 539–553 | 551
Faraday Discussions Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
1/
07
/2
01
6 
13
:2
6:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineOne way to understand this is to notice that the incoming s-polarised light
excites the resonant in-plane plasmon modes in the sample, without itself
signicantly interacting with the probe (which is a very poor antenna to anything
but light polarised perpendicularly to the surface). For most biomedical experi-
ments, it is the chemical contrast that is of interest, so both incoming and
backscattered channels are p-polarised, as this is the polarisation that interacts
with the tip and the sample most strongly (Fig. 5 inset). In all cases great care
needs to be taken to avoid light backscattered from any of the optical components
in the setup from reaching the QCL.
3.1.3 Demonstration images from the QCL s-SNOM. As well as the optical
image, the s-SNOM can be operated as a standard AFM, and Fig. 6 shows the
morphological information of a blood cell, taken from a deparaﬃnised FFPE
biopsy slice, similar to those used in the Digistain experiments of Section 2. The
lower trace is an early s-SNOM image, taken at a wavelength where stable QCL
operation was possible. It's recorded at a 67 nm pixel resolution, and clearly
records the cell structure at a l/140 resolution.
From the eld of natural biophotonics, there are a number of iridescent
beetle species that have evolved with periodic “photonic crystal” chiral shells,
which give them distinctive markings that are visible only in circularly polar-
ised light (Fig. 7). The question arises as to whether the chirality behind this is
an accidental “self-organisation” eﬀect arising from the natural chirality of the
biomolecules that are forming the periodic structure in the shell, or whether
the chirality has been generated by evolutionary forces. Fragments of the shell
were polished to yield a smooth surfaced sample with minimal morphological
contrast in the AFM image. The s-SNOM image however uses the chemical
contrast to reveal the periodic structure of the chitin helices thought to be the
origin of the eﬀect.
Fig. 8 images a eld eﬀect transistor (FET) device fabricated for a graphene
sheet grown epitaxially on a SiC substrate.16,17 The AFMmorphology image reveals
the device structure. The s-SNOM phase image, in this example, approximately
corresponds to the absorption in the graphene layer, and reveals regions of
diﬀering thickness, and the edge eﬀects responsible for the device operation.
At the time of writing the QCL s-SNOM system is being reengineered to facil-
itate tuneable, full-spectrum spectroscopic imaging. The aim is to substantially
increase the amount of scientic information that can be inferred from these
images, and we hope to have new data to present at the meeting itself.
4. Conclusions
We have presented here two new ways of using mid-IR chemical imaging, and in
both cases, as bets the topic of this discussion meeting, the focus has been on
what they can oﬀer the biomedical community. They are both at very diﬀerent
stages of technical readiness, and they face very diﬀerent challenges in the future.
For Digistain the technical hurdles have been overcome, the clinical potential
has essentially already been proven; the challenge now is to validate it using
criteria and methods that will engage the support and interest of the clinicians.
This is already underway, but we are well aware that it will have to be achieved on
a wide enough scale to convince investors to produce them as tools to put in the
medics’ hands, because without that, the idea will come to nothing.552 | Faraday Discuss., 2016, 187, 539–553 This journal is © The Royal Society of Chemistry 2016
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View Article OnlineFor the s-SNOM it is the beginning, and the challenges are still mostly tech-
nical. We believe it has a very bright future as a new scientic research tool for
a wide range of biomedical problems, but, already, we are on the lookout for that
elusive “unmet need”.
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